跳至主要内容
临床试验/NCT01070277
NCT01070277Unknown不适用

Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea

Sheba Medical Center2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2012年3月最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
100
试验地点
2
主要终点
improvement in gastrointestinal complaints

研究概览

简要总结

Study hypotheses is that Antiparasitic therapy in patients with chronic diarrhea after travel to a developing country, with a negative stool findings, will be significantly effective in eliminating diarrhea and other gastro-intestinal complaints compared to similar patients receiving placebo.

详细描述

It is common to encounter travelers from developing countries who suffer from persistent diarrhea after returning home. In many cases repeated stool samples are negative for bacteria, parasites and helminthes and the cause of the diarrhea is not found.

The main debate is whether this condition is a persistent parasitic infection (unidentified) or post-infectious irritable bowel syndrome.However, clinical experience suggests that some of these travelers respond to antiparasitic therapy.

This study aims to answer the question whether antiparasitic treatment in these cases is beneficial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diarrhea (3 or more soft stools per day) for at least two weeks after a trip to a developing country in the past year
  • Stool sample negative for bacteria, parasites and helminthes at least once
  • Has not received, until now, antiparasitic or antihelminthic therapy

排除标准

  • Bloody diarrhea
  • Fever during enrolment
  • Allergy to the offered medication

研究组 & 干预措施

Placebo arm

Placebo Comparator

2 placebo pills X2 /day for 2 days followed by

1 placebo Pill X2 / day for 7 days

干预措施: Placebo control (Drug)

Tinidazole and Albendazole treatment

Experimental

Tinidazole 1 gram BID for 2 days followed by Albendazole 400mg BID for 7 days

干预措施: Tinidazole and Albendazole (Drug)

结局指标

主要结局

improvement in gastrointestinal complaints

时间窗: 3 months

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Prof. Eli Schwartz MD, DTMH

Director, The Center of Geographic Medicine

Sheba Medical Center

研究点 (2)

Loading locations...

相似试验